Drugs targeting the CD47 signaling are currently evaluated in clinical studies and are represented by humanized antibodies including Hu5F9-G4 [(in AML, MDS and r/r B-cell Non-Hodgkin Lymphoma (NHL)] and CC-90002 (in AML, MDS and CD20+ NHL patients), respectively. This evidence concerns the gene CD47 and acute myeloid leukemia.